OVERVIEW

ARA-290 16 mg is a synthetic peptide, also known by the research name cibinetide, derived from a specific tissue-protective region of the naturally occurring protein erythropoietin (EPO). Unlike full-length EPO, which stimulates red-blood-cell production, ARA-290 selectively engages the “innate repair receptor” (IRR) — a cell-surface complex that becomes upregulated in response to stress or injury — to trigger anti-inflammatory, cytoprotective, and tissue-repair signaling pathways without causing erythropoiesis. Preclinical research and early clinical studies have explored its potential effects on nerve health, inflammation modulation, metabolic control, and wound healing, and limited human Phase II data suggest possible benefits in conditions like diabetic neuropathy and small fiber nerve damage.

Despite scientific interest, ARA-290 is not approved by the U.S. Food and Drug Administration or other major regulators for medical use, and it remains classified as an investigational research compound. Products marketed with 16 mg of ARA-290 are typically supplied as high-purity lyophilized powder for laboratory study only and are not intended to diagnose, treat, cure, or prevent any disease. Because controlled evidence on long-term safety, effective dosing, and real-world outcomes in humans is limited, ARA-290 should not be self-administered outside of authorized research settings, and anyone considering participation in clinical trials or peptide research should consult qualified healthcare professionals.